Table 2 Characteristics of ICU lengh stay and therapeutic strategy
|  | Number of patients (%) | Survivors (n = 21) | Non-survivors (n = 53) | P-value |
|---|---|---|---|---|
Type of ICU | 0.11 | |||
 Medical, n (%) | 53 (71.6) | 13 (61.9) | 40 (75.5) |  |
 Surgical, n (%) | 13 (17.6) | 3 (14.3) | 10 (18.9) |  |
 Polyvalent, n (%) | 8 (10.8) | 5 (23.8) | 3 (5.7) |  |
Year of admission | 0.70 | |||
Antifungal treatment | ||||
 Treatment including L-AmB | 56 (75.7) | 19 (90.5) | 37 (69.8) | 0.08 |
 L-AmB alone, n (%) | 44 (59.5) | 14 (66.7) | 30 (56.6) | 0.60 |
 Association of L-AmB + other drug, n (%) | 12 (16.2) | 5 (23.8) | 7 (13.2) | 0.30 |
 Triazole drug alone, n (%) | 4 (5.4) | 1 (4.8) | 3 (5.7) | 1 |
 Echinocandine alone, n (%) | 1 (1.4) | 0 (0) | 1 (1.9) | 1 |
 None, n (%) | 13 (17.6) | 1 (4.8) | 12 (22.6) | 0.09 |
 Delay of efficient antifungal treatment, mean (SD)a | 9.5 (9.9) | 8.2 (7.6) | 10.1 (11.3) | 0.45 |
Interventions | ||||
 Surgical intervention, n (%) | 27 (36.5) | 12 (57.1) | 15 (28.3) | 0.03 |
 Cutaneous resection | 11 (14.9) | 3 (14.3) | 8 (15.1) | 1 |
 Lung resection | 7 (9.5) | 6 (28.6) | 1 (1.9) | 0.002 |
 Amputation | 2 (2.7) | 2 (9.5) | 0 | 0.08 |
 ENT resection | 4 (5.4) | 1 (4.8) | 3 (5.7) | 1 |
 Abdominal resection | 3 (4.1) | 0 | 3 (5.7) | 0.55 |
 Vasopressors, n (%) | 53 (71.6) | 9 (42.9) | 44 (83.0) | 0.001 |
 Mechanical ventilation, n (%) | 66 (89.2) | 14 (66.7) | 52 (98.1) | < 0.001 |
 Renal replacement therapy, n (%) | 31 (41.9) | 5 (23.8) | 26 (49.1) | 0.07 |